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Background: Colorectal cancer is one of the most common malignant tumors worldwide. Loss of imprinting (LOI)
of the insulin-like growth factor 2 (IGF2) gene is an epigenetic abnormality observed in human colorectal
neoplasms. Our aim was to investigate the feasibility of using the IGF2 imprinting system for targeted gene therapy
of colorectal cancer.
Results: We constructed a novel oncolytic adenovirus, Ad315-E1A, and a replication-deficient recombinant
adenovirus, Ad315-EGFP, driven by the IGF2 imprinting system by inserting the H19 promoter, CCCTC binding
factor, enhancer, human adenovirus early region 1A (E1A) and enhanced green fluorescent protein (EGFP) reporter
gene into a pDC-315 shuttle plasmid. Cell lines with IGF2 LOI (HCT-8 and HT-29), which were infected with
Ad315-EGFP, produced EGFP. However, no EGFP was produced in cell lines with maintenance of imprinting
(HCT116 and GES-1). We found that Ad315-E1A significantly decreased cell viability and induced apoptosis only in
LOI cell lines in vitro. In addition, mice bearing HCT-8-xenografted tumors, which received intratumoral
administration of the oncolytic adenovirus, showed significantly reduced tumor growth and enhanced survival.
Conclusions: Our recombinant oncolytic virus targeting the IGF2 LOI system inhibits LOI cell growth in vitro and
in vivo, and provides a novel approach for targeted gene therapy.
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Malignant neoplasms are responsible for nearly 7.5 million
deaths representing 13% of all mortality and 5% of the glo-
bal burden of disease in terms of disability-adjusted life
years lost [1]. Colorectal cancer is the third most common
cancer in men (10% of the total) and the second in women
(9.4% of the total) worldwide [2]. Conventional che-
motherapeutic agents, although often effective, are highly
toxic because of their lack of selectivity for cancer cells.
As a result, efforts have focused on developing* Correspondence: sk_wang@njmu.edu.cn; jifan@stanford.edu
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reproduction in any medium, provided the orinterventions that target tumor-specific genes using tech-
niques to construct tumor-selective replicating viruses.
Genomic imprinting is an epigenetic modification of a
gene based on its parental origin, which results in monoal-
lelic expression [3]. For most genes, both paternal and ma-
ternal alleles are expressed, but for some genes, only one
allele is expressed, which is known as maintenance of
imprinting (MOI). In contrast, loss of imprinting (LOI) is
the reactivation of the silenced allele of an imprinted gene,
leading to perturbation of monoallelic expression. LOI is
closely related to the occurrence of malignant tumors [4].
The first endogenous imprinted gene identified was
mouse insulin-like growth factor 2 (IGF2) encoding a crit-
ical fetal-specific growth factor that is only expressed from
the allele inherited from the father [5]. IGF2 and H19
genes are reciprocally imprinted, and regulated by the en-
hancer, DNA differentially methylated domain (DMD),. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Analysis of p53 mutation and IGF2 gene
imprinting in human tumor cells
Cell lines p53 status IGF2 Imprinting
GES-1 Wild type MOI
HCT116 Wild type MOI
HCT8 Wild type LOI
HT29 Mutation LOI
LOI: Loss of IGF2 imprinting; MOI: Maintenance of IGF2 imprinting.
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underlying this reciprocal imprinting proposes a critical
role for CCCTC binding factor (CTCF) that binds to the
unmethylated maternal DMD. Binding of target sequence
elements by CTCF can block the interaction between
enhancers and promoters, thereby limiting the activity of
enhancers for certain functional domains. In recent years,
researchers have elucidated the important roles of methy-
lated regions and CTCF complexes that combine with the
unmethylated maternal DMD of IGF2 imprinting [6-9]. Hu
et al. [6] transferred nuclei from human tumor cells to show
loss of IGF2 imprinting in enucleated mouse and human
fibroblasts that had maintained normal IGF2 imprinting.
After nuclear transfer, the abnormal tumor epigenotype
was corrected by in vitro reprogramming, suggesting that
LOI is associated with the loss of activity of non-CTCF
trans-imprinting factor(s) that are either inactivated or
mutated in tumors. In addition to blocking enhancers,
CTCF can act as a chromatin barrier by preventing the
spread of heterochromatin structures. In mice, it has been
shown that CTCF serves as a strategic protein that imple-
ments DNA loops [7,8] and helps to silence DNA regions
by binding and recruiting the polycomb repressive complex
2 [9]. Recently, Zhang et al. [10] extended the examination
of the role of CTCF in orchestrating long-distance intra-
chromosomal looping in the human IGF2/H19 imprinting
domain, and demonstrated that interruption of intrachro-
mosomal looping by CTCF decoy proteins abrogates
genomic imprinting of human IGF2. This observation con-
firmed that the inactivation or mutation of CTCF com-
plexes is closely associated with the epigenetic IGF2 LOI in
tumor cells. In our previous study, we found that loss of
IGF2 imprinting is present in both colorectal tissues and
cancer cell lines (HCT-8, HT-29, HCT15, and SW1222).
No such phenomenon has been observed in normal tissue
cells [6]. Furthermore, we successfully confirmed targeted
tumor gene therapy based on IGF2 LOI [11].
Adenoviruses rapidly infect a broad range of human
cells, including proliferating and quiescent cells, which
tend to yield high levels of adenoviral particles [12]. In
addition, adenoviral vectors are relatively easy to ma-
nipulate, purify and manufacture using recombinant
DNA techniques, and transgenes generally do not
undergo changes during successive rounds of viral repli-
cation. On the other hand, adenoviral vectors have poor
targeting toward tumors and a low efficiency of gene
transfer [13]. Abnormal biological characters shared by
multiple cancers have enabled optimization of genetic-
ally engineered viruses that replicate exclusively in
tumor cells (termed replication-selective adenoviral vec-
tors), while not affecting normal cells. Adenovirus H101
has been clinically approved in China for the treatment
of several malignancies. E1B and parts of the E3 regions
have been deleted in this virus that cannot normallyreplicate and only lyses cells in which p53 is inactive.
The cell cycle gatekeeper p53 is commonly observed to
be inactive in tumors. Our present study includes four
cell lines that have various IGF2 imprinting and p53
mutations (Table 1), and infection with H101 serves as
the positive control.
In our previous study, a recombinant replication-
defective adenovirus carrying the IGF2 imprinting sys-
tem and the DT-A gene was successfully constructed, in
which Ad-DT-A effectively kills tumor cells showing
IGF2 LOI [11]. Replication-defective adenoviral vectors
cannot continuously renew after initial activation, result-
ing in only transient expression of the DTA gene in LOI
colorectal cancer cells.
One of the critical functions of the human adenovirus
early region 1A (E1A) protein is to activate transcription
of early viral genes [14]. This region activates viral gene
expression by interacting with and recruiting cellular
transcription machinery to the regulatory regions of
early viral genes. Recent evidence indicates that the Ad5
E1A gene has a tumor suppressor role and exhibits a
dual anti-tumor effect [15]. The E1A protein inhibits
over-expression of erbB2 and protease genes, blocks NF-
Kβ activity and then, as an antitumor effect, increases
the expression of nm23 and p53 proteins [16]. Further-
more, E1A protein induces cell cycle progression from
G0/G1 to S phase by binding and repressing the func-
tion of intracellular proteins such as pRb and p300, lead-
ing to cancer cell lysis by massive up-regulation of viral
replication [17]. In this study, we constructed a novel
replication-selective adenovirus based on the IGF2 LOI
system to target colorectal cancers.
Results
Construction and characterization of the oncolytic
adenovirus Ad315-E1A
The oncolytic adenovirus Ad315-E1A was successfully
constructed in this study, which was regulated by the
IGF2 imprinting system. A control virus, Ad315-EGFP,
was also constructed (Figure 1). In MOI cells, the active
CTCF complex can bind to the DMD, blocking the ac-
tivity of the enhancer and inhibiting the expression of
downstream genes, but the inactive CTCF complex in
LOI cells cannot bind to the DMD, leading to increased
ITR enhancers DMD H19 E1A poly A
CTCF
enhancers DMD H19 EGFP
CTCF
enhancers DMD H19 E1A















Figure 1 Construction and expression characterization of Ad315-E1A and Ad315-EGFP in cell lines with different IGF2 imprinting
status. (a) In IGF2 MOI cell lines, CTCF binding factors are bound to DMD sites and the enhancer cannot control the H19 promoter, resulting in
no expression of E1A or EGFP. (b) In IGF2 LOI cell lines, H19 has promoter activity that initiates expression of the downstream sequence due to
CTCF complex regression. ITR: inverted terminal repeats.
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activation by the enhancers.
To test the applicability of the expression system, we
used an enhanced green fluorescent protein (EGFP) re-
porter gene. After infection of cells with Ad315-EGFP (10
plaque-forming units [PFU]/cell) for 24 h, EGFP expres-
sion was observed in LOI cells lines HCT-8 and HT-29.
However, in the HCT116 cell line, which maintains nor-
mal IGF2 imprinting, only weakly positive EGFP expres-
sion was observed (Figure 2). Thus, the viral gene therapy
system only expressed the reporter gene in cells with ab-
normally maintained IGF2 imprinting.
We also examined E1A mRNA expression in four can-
cer cell lines (HCT-8, HT-29, HCT116, and GES-1) that
were infected with Ad315-E1A and H101 (10 PFU/cell).
Cells were harvested at 24 h after infection to determine
E1A mRNA expression by RT-PCR, and E1A protein ex-
pression was determined by western blot at 48 h after
infection. As shown in Figure 3, in the Ad315-E1A
group, E1A mRNA and protein were expressed in LOI
cell lines (HCT-8 and HT-29), but not in the MOI cell
line (HCT116) and normal cell line (GES-1). H101 infec-
tion resulted in obvious E1A mRNA and protein expres-
sion in the p53 mutant cell line HT-29 compared withthat in p53 wild-type cell lines (HCT116, HCT-8, and
GES-1).
Growth inhibition and cytotoxicity of LOI tumor cells by
Ad315-E1A infection
We were interested in examining whether Ad315-E1A treat-
ment would effectively suppress tumor cell proliferation. For
this purpose, the cytotoxic effects of the oncolytic adeno-
virus expressing the E1A gene were investigated in all cell
lines. As shown in Figure 4a, the MOI cell line HCT116
and normal cell line GES-1, which were infected with
Ad315-E1A, remained fully viable for 72 h after infection.
However, the LOI cell lines (HCT-8 and HT-29) displayed
decreased viability (p < 0.05). Growth inhibition was also
improved compared with that of H101-infected cells with
various p53 activities. The LOI-targeting oncolytic adeno-
viral vector Ad315-E1A induced cytopathic effects as effi-
ciently as that of the oncolytic adenovirus H101 in the
LOI and p53-inactive cell line (HT-29), whereas the
growth inhibition ability of H101 was more strongly atte-
nuated in the wild-type p53 and LOI cancer cell line
(HCT-8) (p > 0.05).
We further examined apoptosis in all cell lines with
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Figure 3 E1A mRNA and protein expression in cells infected with adenoviral vectors carrying the E1A gene. (a) RT-PCR analysis of E1A
mRNA expression in four cell lines at 24 h after infection with Ad315-E1A or H101 (10 PFU/cell). (b) Western blot analysis of E1A protein
expression in four cell lines at 48 h after infection with Ad315-E1A or H101 (10 PFU/cell). In the Ad315-E1A group, E1A mRNA and protein were
expressed in HCT-8 and HT-29 cells, but not in GES-1 and HCT116 cells. E1A mRNA and protein expression was only detected in the P53 mutant
cell line HT-29 in the H101 group.
Figure 2 Cell-specific expression of EGFP in four cell lines infected with recombinant adenoviral vectors. (a) Positive expression of EGFP in
LOI cell lines. Ad315-EGFP infection (10 PFU/cell) induced EGFP expression in HCT-8 and HT-29 cells. (b) Negative expression of EGFP in MOI cell lines.
Fluorescence images show no EGFP expression in GES-1 cells and only weak EGFP expression in HCT116 cells infected with Ad315-EGFP (10 PFU/cell).
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Figure 4 In vitro effect of adenoviral vectors carrying the E1A gene. (a) Cell viability was determined by an MTT assay at 72 h after infection
with recombinant adenoviral vectors (10 PFU/cell). Graphs are representative of three separate experiments. (b) Apoptosis was investigated using
flow cytometric analysis at 72 h after infection with Ad315-E1A, Ad315-EGFP or H101 (10 PFU/cell). The bottom right quadrants in dot plots show
the apoptosis of various cell lines infected with Ad315-E1A. Data are representative of three separate experiments.
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http://www.molecular-cancer.com/content/11/1/86after infection. Ad315-EFGP infection served as a nega-
tive control to enable us to evaluate the cytopathic effect
of adenoviral infection itself. As shown in Figure 4b, the
percentages of cells undergoing apoptosis in LOI cell




















Figure 5 Anti-tumor activity of Ad315-E1A in HCT-8 xenograft model
treatments. Values represent the means ± SD for eight mice per group. Sta
**p < 0.01 vs. tumor volume of the Ad315-EGFP group. (b) Percentage of m20%, respectively, which was higher than that in the con-
trol group at 3% (p < 0.01). In contrast, the percentage
of apoptosis in HCT116 cells with normal IGF2 imprint-
ing was not increased compared with that in the control



















s. (a) Average volume of subcutaneous tumors after receiving various
tistical differences were evaluated by one-way analysis of variance.
ouse survival analyzed by the Kaplan-Meier method.
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difference in HT-29 colorectal carcinoma cells at the
same multiplicity of infection (p > 0.05).
Antitumor efficacy of Ad315-E1A in nude mice
Considering the potential of Ad315-E1A treatment
in vitro, we investigated its antitumor efficacy in vivo. As
shown in Figure 5a, tumor growth was slower in the
Ad315-E1A-treated group than that in other groups. On
day 30 after treatment initiation, the mean tumor
volumes of phosphate-buffered saline (PBS)-, Ad315-
EGFP- and Ad315-E1A-treated mice were 1342.4,
1145.0, and 451.8 mm3, respectively. Although no sig-
nificant difference existed between PBS- and Ad315-
EGFP-treated groups, significant antitumor efficacy was
observed in the Ad315-E1A-treated group compared
with that in other groups (p < 0.05). Moreover, the mean
survival times for mice treated with PBS, Ad315-EGFP
or Ad315-E1A were 37, 40 and 88 days, respectively.
Ad315-EGFP treatment did not increase the survivalFigure 6 Enhanced E1A expression and apoptosis in vivo by Ad315-E
on day 7 after treatment (H&E staining; original magnification: ×100). (b) E1
(c) Cell apoptosis in tumors after receiving the last treatment, as measured
expression rate and apoptosis percentage.time, compared with that of PBS treatment (p > 0.05),
but Ad315-E1A treatment prolonged the survival time
compared with that of treatment with PBS or Ad315-
EGFP (p < 0.05, Figure 5b).
E1A expression and apoptotic cells in tumors
Hematoxylin and eosin (H&E)-stained xenograft sections
from Ad315-E1A-treated mice showed pathological
signs of tumor necrosis obviously exceeding that
of other groups (Figure 6a). To better understand
the mechanism underlying the enhanced anti-tumor ac-
tivity, we measured E1A protein expression and apop-
tosis in tumors. E1A protein was measured by
immunohistochemical staining of tumor samples col-
lected on day 7 after treatment (Figure 6b). E1A protein
was observed at low levels in pathological sections from
mice treated with Ad315-EGFP or PBS alone. However,
in pathological sections infected by Ad315-E1A, E1A
protein expression was markedly increased. The expres-
sion rates of E1A protein in HCT-8 cells treated with1A treatment. (a) Histopathological responses in xenografted tumors
A protein expression as measured by immunohistochemical staining.
by a TUNEL assay. Original magnification: ×400. (d) Analysis of the E1A
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0.2 and 20 ± 5%, respectively.
In agreement with E1A protein expression, terminal
deoxynucleotide transferase-mediated dUTP nick-end
labeling (TUNEL) assays revealed large numbers of
apoptotic cells in tumors infected with Ad315-E1A
(Figure 6c). In mice that received PBS or Ad315-EGFP,
apoptotic cells were sparsely distributed in sections. The
apoptotic indexes of HCT-8 tumor xenografts treated
with PBS, Ad315-EGFP or Ad315 -E1A were 4 ± 2, 7 ±
3 and 32 ± 7%, respectively. Thus, the efficacy of tumor
therapy was closely related to the enhanced apoptosis
induced by Ad315-E1A infection.
Discussion
In the present study, we successfully constructed a novel
replication-selective adenovirus, Ad315-E1A, and a
replication-deficient adenovirus, Ad315-EGFP. Our data
show a significant effect of Ad315-E1A against tumor
growth both in vitro and in vivo. This observation sug-
gests that replication-selective adenoviruses driven by
the IGF2 imprinting system may be used as a novel anti-
cancer agent with a high therapeutic potential.
Using viruses as a genetic carrier offers an attractive
alternative or promising integration with traditional
therapeutic regimens for cancer treatment [18]. Among
viral-based therapies and oncolytic agents, adenoviruses
have emerged as a promising vector that is already being
used for the treatment of solid tumors in humans [19].
Adenoviruses are non-enveloped viruses with linear
double-stranded DNA, which infect cells by binding to
the coxsackie and adenovirus receptor expressed on the
surface of target cells [20]. As vectors for oncolytic ther-
apies, these viruses have many advantages over other
vectors, including the capability of transducing and rep-
licating in dividing and non-dividing cells, their ease
of manipulation, and a naturally lytic replication cycle
[21-24]. All of these features highlight the utility of ade-
noviruses for in vitro production and in vivo curative
effects [25]. Since 1993, more than 300 clinical trials based
on adenoviral vectors have been performed [20] with
promising outcomes. The first clinical results of trials
based on adenoviruses as an oncolytic therapeutic agent
have been promising, and show the clinical safety and
feasibility of this approach [26]. In our study, we con-
structed an oncolytic adenoviral vector and demonstrated
its effective killing of cancer cells both in vitro and in vivo.
IGF2 encodes the mitogenic anti-apoptotic peptide IGF-
II that is overexpressed in several human cancers cells. In
colorectal cancer, it has been reported that LOI of IGF2
occurs in 44% of informative colorectal cancers that are
linked to microsatellite instability [27]. Additional studies
have reported a range from 33% to 87% of sporadic colon
cancers that were related to LOI of IGF2 [28,29].Based on these findings, we theorized that we could
build a kind of oncolytic adenovirus specific for replica-
tion in LOI tumor cells for colorectal cancer therapy. In
this proof-of-concept study, we constructed adenoviral
vectors, Ad315-E1A and Ad315-EGFP, which carry the
three enhancer elements, DMD and promoter based on
IGF2 LOI. Initially the utility of our expression system
was tested using EGFP reporter assays. The results
showed that green fluorescence was detected only in
LOI cells. By increasing the multiplicity of infection and
extending the time of infection, we found that the
results were unchanged. To further demonstrate the se-
lective efficacy of the LOI system, we used the oncolytic
adenovirus H101, which has been clinically approved in
China to treat malignancies, as a positive control for
specific lysis of tumor cells by targeting the inactivated
p53 in tumors. We used RT-PCR and western blotting
to detect E1A expression at mRNA and protein levels,
respectively, in Ad315-E1A-infected cells, and confirmed
E1A expression in LOI colorectal cell lines. Furthermore,
in H101-infected cells, E1A mRNA and protein was only
detected in the p53 mutant cell line HT-29. All of the
above results indicate that the replication-selective sys-
tem that we used is practicable and effective.
In this study, the therapeutic potential of Ad315-E1A
was tested by an MTT assay and flow cytometry, and the
results clearly support the rationale of our hypothesis, in
which Ad315-E1A effectively suppressed the growth of
tumor cells and induced obvious cytotoxicity in LOI tumor
cells. Therefore, we compared the therapeutic effect be-
tween IGF2 regulatory sequences and H101 for colorectal
cancer treatment. The data showed that there was no de-
tectable cytotoxicity in HCT-116 and GES-1 cells infected
with Ad315-E1A or H101 (10 PFU/cell), whereas Ad315-
E1A infection achieved significant growth inhibition of the
IGF2 LOI and p53-active cell line (HCT-8) relative to that
by H101 infection. In addition, both oncolytic viruses
exhibited superior efficiency to inhibit growth of the HT-
29 (p53 mutant and LOI) cell line. These results suggest
that the IGF2 LOI system in our viral vector enabled effi-
cient adenovirus replication in host cells using the E1A en-
dogenous promoter.
Using the human colorectal cancer cell line HCT-8 as a
model, we showed that this therapeutic strategy signifi-
cantly increased cancer cell death and apoptosis caused by
virus replication in vivo. Despite Ad315-E1A treatment sig-
nificantly inhibiting tumor growth and prolonging the sur-
vival of tumor-bearing mice, the tumors were not
eliminated completely. Previous research also found that
oncolytic viruses have a limited potential to eradicate
tumors when used as a monotherapy [30-32]. Thus, onco-
lytic viruses are often used in combination with other mo-
dalities, such as chemotherapy [33], radiotherapy [34], or
arming oncolytic adenoviruses with therapeutic genes [35],
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we will investigate appropriate methods to enhance the
potency of the novel recombinant adenovirus for cancer
gene therapy.
Conclusions
In summary, our results show that an oncolytic adenovirus
regulated by the IGF2 LOI system confers a significant
anti-tumor effect by induction of apoptosis in vitro and
in vivo in human colorectal cancer cells. LOI exists in a
wide variety of tumors, and although more investigations
are required for future use, our preliminary data support
the use of oncolytic viruses in the context of the IGF2 LOI
system as a novel approach for cancer therapy.
Methods
Cell lines and culture
HCT-8, HCT116, HT-29 (human colon cancer cell lines)
and GES-1 (normal human cell line) were obtained from
the Shanghai Cell Collection, Chinese Academy of
Sciences. The HEK293 cell line (human embryonic kid-
ney cells containing the E1A region of the adenovirus)
was obtained from Microbix Inc. (Ontario, Canada).
HEK293, GES-1, and HCT-8 cell lines were maintained
in Dulbecco’s modified Eagle’s medium (DMEM;
Hyclone, UT, USA) supplemented with 10% fetal bovine
serum (FBS; Hyclone). HCT116 and HT-29 cells were
maintained in RPMI 1640 (Invitrogen, CA, USA) supple-
mented with 10% FBS. Cells were maintained in a hu-
midified incubator at 37°C with 5% CO2.
Plasmid construction and incorporation into adenoviral
vectors
The original adenoviral shuttle plasmid that we used in
this study was pDC315, and AD5 PBHGLOX1, 3CRE
(Microbix Biosystems, Ontario, Canada). Mouse H19 en-
hancer exons 1 (258 bp) and 2 (360 bp) were amplified
by PCR from mouse genomic DNA and then linked as a
single fragment by PCR. The enhancer was cloned into
the pDC315 plasmid using restriction endonucleases
Xbal and EcoRI. Subsequently, mouse DMD exons 1–2
(429 bp), 3 (207 bp) and 4 (156 bp) were also amplified
by PCR from genomic mouse DNA and then linked as a
single fragment by PCR. The DMD was cloned down-
stream of the enhancer using restriction endonucleases
EcoRI and NheI. The mouse H19 promoter (302 bp)
was amplified by PCR from mouse genomic DNA using
the following primers: forward, 5’ GCGCTAGCCCA
CCGTTCTATGAAGGGCTTC 3’ (containing a NheI
site) and reverse, 5’ AAGGATCCTCATCAGCGCCCA
TCTCTAGCC 3’ (containing a BamHI site), and then
cloned downstream of the DMD using restriction endo-
nucleases NheI and BamHI. The human adenovirus E1A
sequence (1013 bp) was amplified by PCR from a TOP-K plasmid, which was kindly provided by Dr. Ji-Fan Hu
(Stanford University Medical School), using the follow-
ing primers: forward, 5’ CCCGGATCCGGGCCCTAT
GAGACATATTATCT 3’ (containing a BamHI site) and
reverse, CGCGTCGACCGCAATCACAGGTTTACACC
TTA 3’ (containing a SalI site).
The EGFP reporter gene from the pEGFP-C1 vector
(Clontech, Mountain View, CA, USA) and the E1A gene
were then inserted downstream of the H19 promoter using
restriction endonucleases BamHI and SalI to construct
pDC315-enhancer-DMD-H19-EGFP and pDC315-enhan-
cer-DMD-H19-E1A. Inserts were confirmed by DNA se-
quencing. The adenovirus Ad315-E1A was constructed by
homologous recombination techniques using pDC315-en-
hancer-DMD-H19-E1A and the adenovirus packaging
plasmid PBHGLOX1, 3CRE in HEK293 cells with Lipofec-
tamine 2000 (Invitrogen Life Technologies, CA, USA). A
standard replication-deficient adenovirus, Ad315-EGFP,
was constructed by cotransfection of the adenovirus shuttle
vector containing EGFP with an E1A/B-deleted adenoviral
backbone vector.
Adenoviruses were plaque purified, propagated in
HEK293 cells, and purified again by a CsCl gradient
according to standard techniques. Functional particle
titers of all adenoviruses were determined by a plaque
assay using HEK293 cells. The positive control adeno-
virus H101 was kindly provided by Dr. Sheng-Fang Ge
(Shanghai Jiao Tong University School of Medicine).Virus infection
Cells were seeded in 96-well plates at a density of 10,000
cells/well for a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl
tetrazolium bromide (MTT) assay, or in 6-well plates at
a density of 1000,000 cells/well for RT-PCR and flow
cytometric analysis. Then, cells were incubated with
various concentrations of Ad315-EGFP, Ad315-E1A, and
H101 in serum-free DMEM at 37°C for 90 min. After
incubation, serum-free DMEM containing the viruses
was replaced with normal growth medium. The infected
cells were maintained at 37°C until use in assays.EGFP and E1A expression analyses
EGFP expression was examined at 24 h after infection with
adenoviral vectors (10 PFU/cell) under an Axioskop 2
microscope (Carl Zeiss, Oberkochen, Germany) with a
fluorescent filter set (excitation 450–490 nm). E1A mRNA
expression was determined by RT-PCR. Total RNA was
extracted using Trizol (Invitrogen Life Technologies)
according to the manufacturer’s instructions. First strand
cDNA synthesis was performed in a total volume of 25 μl
containing 2 μg RNA, 0.5 μg primer and 200 U M-MLV re-
verse transcriptase. cDNA was subsequently amplified in 50
μl reaction volumes containing 0.4 μmol/l of each E1A
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China). The amplification conditions were pre-denaturation
at 94°C for 5 min, followed by 35 cycles of 94°C for 40 s,
60°C for 40 s and 72°C for 60 s, and a final extension of 72°
C for 7 min. PCR products were electrophoresed on a 1%
agarose gel containing ethidium bromide and then visua-
lized under UV light.
Western blotting to detect E1A protein expression
Cells were harvested and lysed by three cycles of freeze/
thawing at −80°C. Cell lysates were separated by 12% so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
and then transferred onto nitrocellulose membranes
(Amersham Pharmacia Biotech AB, Uppsala, Sweden).
Membranes were probed with a mouse monoclonal anti-
body against E1A (Abcam, Boston, MA, USA) and then
a horseradish peroxidase-conjugated goat anti-mouse
IgG. Proteins were visualized using Lumi-Light Western
Blotting Substrate (Roche Molecular Biochemicals).
Cytotoxicity assay
Cytotoxicity was assessed using an MTT assay that was
performed as described previously using a Cell Counting
Kit-8 (CCK-8; Dojindo Laboratories, Japan) [36]. Briefly,
cells were seeded in 96-well plates at a density of 10,000
cells/well. Then, cells were infected with recombinant
adenoviral vectors (10 PFU/cell). Cell growth and viabil-
ity were assayed at 72 h after incubation with CCK-8 kit
reagents by measuring absorbances at 450 nm in a
microplate reader (Bio-Rad, Richmond, CA, USA). Each
sample was assayed in quadruplicate, and experiments
were repeated at least twice.
Apoptosis assay
Quantitative evaluation of apoptosis was performed using
flow cytometry after double staining with an annexin V-
fluorescein isothiocyanate apoptosis detection kit to dis-
crimination between early apoptotic (annexin V-positive)
and necrotic ( annexin V/propidium iodide double-positive)
cells. The cells (100,000 cells/well) were cultured in 6-well
plates, and then infected with Ad315-E1A at 10 PFU/cell.
Cell apoptosis was analyzed at 72 h after infection with
Ad315-EFGP (10 PFU/cell) serving as a negative control.
Tumor xenografts
Tumor xenografts were established by subcutaneous injec-
tion of 5 × 106 HCT-8 cells into the right flank of 4–6-
week-old female athymic nude mice, which was approved
by the Experimental Animal Center of University of Yangz-
hou, Yangzhou, China. The average tumor volume was
measured by the formula: volume = (length × width2) / 0.5.
When tumors reached approximately 100 mm3, xeno-
grafted mice were randomly divided into three treatment
groups with eight mice in each group. The Ad315-E1Agroup received intratumoral injections of 1 × 108 Ad315-
E1A viral particles three times every other day. Tumors
injected with Ad315-EGFP viral particles at the same dos-
age served as a viral vector control, and those injected with
PBS served as a negative control. The tumor size was mea-
sured by vernier calipers every 3 days. Mice were then
euthanized by cervical dislocation at a predetermined inter-
val of observation. Tumors were dissected out and stored
in 40% formalin. For histological analysis, fixed tumors
were embedded in OCT compound and then cut into 5–7
mm sections using a Cryocut microtome (Leica, Germany).
Mouse survival was recorded in a separate experiment.
Animal experiments were performed in accordance with
institutional guidelines for animal care by Nanjing Medical
University.
Immunohistochemistry
To immunohistochemically stain the E1A protein, the
tumor and neighboring tissues were fixed in 10% forma-
lin and embedded in paraffin for staining. Tumor or tis-
sue sections were incubated at 4°C overnight with a
mouse anti-human E1A antibody (Abcam, Boston, MA,
USA) at a dilution of 1:50. Sections were rinsed in PBS-
T (0.05% Triton X-100 in PBS), followed by incubation
with a goat anti-mouse secondary antibody at a 1:500 di-
lution for 1 h at room temperature. Sections were subse-
quently incubated with streptavidin-horseradish peroxidase
(BD Biosciences) and diaminobenzidine substrate to de-
velop the colorimetric reaction. The number of E1A-
positive cells was counted in five random fields at ×400
magnification under a light microscope and averaged. Only
cells with distinct staining were counted. The positivity rate
was used to grade the expression levels.
TUNEL assay
Apoptosis of tumor cells was detected using a TUNEL
assay performed with an In Situ Cell Death Detection
Kit (Roche, Mannheim, Germany) following the manu-
facturer’s instructions. To stain apoptotic cells, tumor
samples were fixed with 10% formaldehyde and paraffin-
embedded sections were prepared. The number of
TUNEL-positive cells was counted in five random fields
at ×400 magnification under a light microscope, and the
apoptosis index for each field was calculated as the per-
centage of TUNEL-positive cells relative to the total
number of cells.
Statistical analysis
Experimental data were presented as the mean ± stand-
ard deviation (SD) and assessed using the Student’s t-test
and one-way analysis of variance. Differences among the
results of in vivo survival experiments were assessed by
the Kaplan-Meier method. Results were considered sta-
tistically significant at p < 0.05.
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